Matches in Wikidata for { <http://www.wikidata.org/entity/Q66079248> ?p ?o ?g. }
Showing items 1 to 45 of
45
with 100 items per page.
- Q66079248 description "clinical trial" @default.
- Q66079248 description "ensayu clínicu" @default.
- Q66079248 description "klinisch onderzoek" @default.
- Q66079248 description "клінічне випробування" @default.
- Q66079248 name "Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Subjects With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast Cancer" @default.
- Q66079248 name "Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Subjects With Hormone Receptor-positive" @default.
- Q66079248 type Item @default.
- Q66079248 label "Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Subjects With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast Cancer" @default.
- Q66079248 label "Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Subjects With Hormone Receptor-positive" @default.
- Q66079248 prefLabel "Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Subjects With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast Cancer" @default.
- Q66079248 prefLabel "Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Subjects With Hormone Receptor-positive" @default.
- Q66079248 P1132 Q66079248-07599241-AA2A-4C58-B33C-321DE738B068 @default.
- Q66079248 P1476 Q66079248-521C7C4B-01B2-4B07-B1B3-1AB233D9CABB @default.
- Q66079248 P17 Q66079248-17C09114-3281-44F7-8BA2-D70E0A233084 @default.
- Q66079248 P17 Q66079248-29FF2519-442D-46F5-BBBD-CFCC6FD0B88B @default.
- Q66079248 P17 Q66079248-67C7686C-ED01-42A8-9820-79D45C891BF6 @default.
- Q66079248 P17 Q66079248-B3D6BE06-CB5A-4738-87B6-FEA31AAD2E03 @default.
- Q66079248 P17 Q66079248-CEE15C62-172B-415E-9C42-A906E0E6055F @default.
- Q66079248 P17 Q66079248-ED9B9FB1-8A1A-48B6-A982-C5E178BC6093 @default.
- Q66079248 P2899 Q66079248-F30F2131-49D9-4CB0-9F5A-025A268FFC34 @default.
- Q66079248 P3098 Q66079248-AE0C7397-9C6A-4E03-80DA-AC5FABA77232 @default.
- Q66079248 P31 Q66079248-EAFCE255-E4A6-4D1E-A99E-4850368FCB4B @default.
- Q66079248 P580 Q66079248-6F71ECE7-B9D4-4431-936E-70BCE388140A @default.
- Q66079248 P582 Q66079248-A0C97DFE-1D0C-45A0-A720-4934CA407DE0 @default.
- Q66079248 P6099 Q66079248-42446079-142D-471C-BCFB-28793E747209 @default.
- Q66079248 P6153 Q66079248-18F94462-A9C3-47C8-A242-3036C62F2507 @default.
- Q66079248 P8363 Q66079248-BACA770B-B417-47DB-8591-F58F2FCDE932 @default.
- Q66079248 P859 Q66079248-3C0705A6-C3F3-401A-9385-ADEE733F0860 @default.
- Q66079248 P1132 "+294" @default.
- Q66079248 P1476 "A Phase I/II Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Combination With Fulvestrant in Subjects With HR+/HER2- Advanced or Metastatic Breast Cancer" @default.
- Q66079248 P17 Q142 @default.
- Q66079248 P17 Q145 @default.
- Q66079248 P17 Q16 @default.
- Q66079248 P17 Q29 @default.
- Q66079248 P17 Q30 @default.
- Q66079248 P17 Q408 @default.
- Q66079248 P2899 "+18" @default.
- Q66079248 P3098 "NCT02964507" @default.
- Q66079248 P31 Q30612 @default.
- Q66079248 P580 "2017-02-02T00:00:00Z" @default.
- Q66079248 P582 "2021-01-16T00:00:00Z" @default.
- Q66079248 P6099 Q42824440 @default.
- Q66079248 P6153 Q212322 @default.
- Q66079248 P8363 Q78089383 @default.
- Q66079248 P859 Q212322 @default.